The evolutionary conserved miR-137/325 tandem mediates obesity-induced hypogonadism and metabolic comorbidities by repressing hypothalamic kisspeptin

Background: Obesity-induced hypogonadism (OIH) is a prevalent, but often neglected condition in men, which aggravates the metabolic complications of overweight. While hypothalamic suppression of Kiss1-encoded kisspeptin has been suggested to contribute to OIH, the molecular mechanisms for such repre...

Descripción completa

Detalles Bibliográficos
Autores: Avendaño, María S., Perdices Lopez, Cecilia, Guerrero-Ruiz, Yolanda, Ruiz-Pino, Francisco, Rodriguez-Sanchez, Ana B., Sanchez-Tapia, María J., Sobrino, Verónica, Pineda, Rafael, Barroso, Alexia, Correa-Sáez, Alejandro, Lara-Chica, Maribel, Fernandez-Garcia, José C., García Redondo, Ana Belén, Hernanz, Raquel, Ruiz-Cruz, Miguel, Garcia-Galiano, David, Pitteloud, Nelly, Calzado, Marco A., Briones Alonso, Ana María, Vázquez, María J., Tena-Sempere, Manuel
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/719916
Acceso en línea:http://hdl.handle.net/10486/719916
https://dx.doi.org/10.1016/j.metabol.2024.155932
Access Level:acceso abierto
Palabra clave:Comorbidities
Kiss1
Kisspeptins
Male hypogonadism
MicroRNAs
miR-137
miR-325
Obesity
Obesity-induced hypogonadism
Medicina
Descripción
Sumario:Background: Obesity-induced hypogonadism (OIH) is a prevalent, but often neglected condition in men, which aggravates the metabolic complications of overweight. While hypothalamic suppression of Kiss1-encoded kisspeptin has been suggested to contribute to OIH, the molecular mechanisms for such repression in obesity, and the therapeutic implications thereof, remain unknown. Methods: A combination of bioinformatic, expression and functional analyses was implemented, assessing the role of the evolutionary-conserved miRNAs, miR-137 and miR-325, in mediating obesity-induced suppression of hypothalamic kisspeptin, as putative mechanism of central hypogonadism and metabolic comorbidities. The implications of such miR-137/325-kisspeptin interplay for therapeutic intervention in obesity were also explored using preclinical OIH models. Results: MiR-137/325 repressed human KISS1 3’-UTR in-vitro and inhibited hypothalamic kisspeptin content in male rats, while miR-137/325 expression was up-regulated, and Kiss1/kisspeptin decreased, in the medio-basal hypothalamus of obese rats. Selective over-expression of miR-137 in Kiss1 neurons reduced Kiss1/ kisspeptin and partially replicated reproductive and metabolic alterations of OIH in lean mice. Conversely, interference of the repressive actions of miR-137/325 selectively on Kiss1 3’-UTR in vivo, using target-site blockers (TSB), enhanced kisspeptin content and reversed central hypogonadism in obese rats, together with improvement of glucose intolerance, insulin resistance and cardiovascular and inflammatory markers, despite persistent exposure to obesogenic diet. Reversal of OIH by TSB miR-137/325 was more effective than chronic kisspeptin or testosterone treatments in obese rats